Karuna Therapeutics Sees Breakthrough In Schizophrenia Drug
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
U.S. health regulators are warning consumers not to use more than two dozen varieties of over-the-counter eyedrops because of the risk of infections that could lead to blindness.
